US shoe firm gets kicked for butt claims

US shoemaker Skechers is to pay $40 million to settle claims that it deceived consumers by suggesting its sports shoes could help tone their butts and lose weight, officials said Wednesday.

In an agreement similar to one last year against Reebok, the (FTC) said purchasers of the California-based firm's Shape-up, Resistance Runner, Toners and Tone-up shoe ranges can apply for refunds.

The Shape-ups ads featured stars including Kim Kardashian and Brooke Burke. In one which aired during the 2011 Super Bowl, Kardashian was shown dumping her personal trainer for a pair of Shape-ups.

"Skechers' unfounded claims went beyond stronger and more toned muscles. The company even made claims about weight loss and ," said David Vladeck, director of the FTC's Bureau of Consumer Protection.

"The FTC's message, for Skechers and other national advertisers, is to shape up your substantiation or tone down your claims," he added.

California Attorney General Kamala Harris added: "Consumers shouldn't be duped into paying more for products with false promises of weight loss and other benefits."

The settlement was part of a wider agreement resulting from an investigation involving 44 states and the District of Columbia.

Last September, sportswear giant Reebok, a unit of the German group Adidas, agreed to pay $25 million in customer refunds to purchasers of its EasyTone and RunTone .

Related Stories

FTC, diet pill marketers settle for $25M

date Jan 05, 2007

The U.S. Federal Trade Commission recovered $25 million as a settlement in its cases alleging deceptive advertising against marketers of four diet pills.

US cracks down on acai berry sellers

date Apr 19, 2011

US regulators on Tuesday announced a crackdown on websites that sell acai berry weight loss products using fake endorsements from news sites such as CNN, Fox News and USA Today.

Recommended for you

Cardinal Health paying $26.8 million in FTC settlement

date 12 hours ago

Cardinal Health will pay $26.8 million as part of a settlement with the Federal Trade Commission over charges it monopolized the sale in 25 markets of diagnostic drugs known as low-energy radiopharmaceuticals.

Selecting the right tool for the job

date Apr 14, 2015

Randomized clinical trials of new drugs have long been considered the "gold standard" in determining safety and efficacy before drugs, biologics, vaccines or devices are introduced to the general public. However, in the case ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.